GPI 5693
Latest Information Update: 17 Mar 2008
At a glance
- Originator MGI GP
- Class Neuroprotectants
- Mechanism of Action Glutamate carboxypeptidase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Cerebral ischaemia; Diabetic neuropathies; Glaucoma; Neuropathic pain; Prostate cancer
Most Recent Events
- 25 Jul 2006 This programme is still in active development with MGI GP
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP
- 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma